Lv32
250 积分 2024-08-14 加入
Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial
2小时前
已完结
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC
2天前
已完结
Lung cancer treatment: 20 years of progress
17天前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
MET alterations in advanced non-small cell lung cancer
1个月前
已完结
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
NTRK fusions in colorectal cancer: clinical meaning and future perspective
1个月前
已完结
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
2个月前
已完结
Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD
3个月前
已完结
Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway
3个月前
已完结
皖公网安备34019202002308
